Escugen
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A gene therapy company developing CRISPR-based curative treatments for genetic diseases.
Genetic DisordersOncology
Technology Platform
Proprietary CRISPR-based gene editing platform focused on novel editors and delivery systems for ex vivo and in vivo therapies.
Opportunities
Potential to create transformative, one-time cures for diseases with high unmet need and no effective treatments.
Risk Factors
Faces substantial scientific, safety, and manufacturing challenges inherent to first-generation gene editing therapies.
Competitive Landscape
Operates in the highly innovative but crowded global gene editing arena, requiring clear differentiation in technology or indications.